EMA Authorised: Lenalidomide Krka d.d. Novo mesto (previously Lenalidomide Krka) (lenalidomide hydrochloride monohydrate) — Krka, d.d., Novo mesto

View source ↗

Summary

EMA authorised lenalidomide Krka d.d. Novo mesto for indications including multiple myeloma and follicular lymphoma, establishing its market authorization.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma Follicular
• Multiple Myeloma

Drugs mentioned

• Lenalidomide Krka d.d. Novo mesto (lenalidomide hydrochloride monohydrate)

Snippet

Status: Authorised. Therapeutic area: Multiple Myeloma;Lymphoma, Follicular. MAH: Krka, d.d., Novo mesto. Decision date: 13/12/2021